Department of Orthopaedic Surgery, Chonnam National University Medical School and Hospital, 322, Seoyang-ro, 58128, Hwasun, Republic of Korea.
Int Orthop. 2023 Nov;47(11):2727-2735. doi: 10.1007/s00264-023-05895-7. Epub 2023 Aug 5.
To demonstrate the clinical outcomes of patients with fungal periprosthetic joint infections (PJIs) after two-stage exchange arthroplasty combined with antifungal therapy.
We retrospectively reviewed the outcomes of 41 patients with fungal PJIs after primary total knee arthroplasty (TKA) in a single centre from January 1999 to October 2017. During the first stage of resection arthroplasty, antifungal-impregnated cement spacers (AICSs) were implanted in all patients. After systemic antifungal treatment during the interval between the two surgeries, delayed reimplantation as part of a two-stage exchange protocol was performed when patients were clinically stable. We defined treatment success as a well-functioning arthroplasty without any signs of PJI after a minimum follow-up of two years without antimicrobial suppression. Successful treatment was confirmed by repeat negative cultures as well as a return of inflammatory markers to normal levels.
The treatment success rate was 63.4% at the final follow-up. Thirty-six of 41 patients (87.8%) met the criteria for second-stage revision after confirmation of complete infection control. The mean prosthesis-free interval was 6.6 months (range, 2.0-30.0 months). During follow-up after two-stage exchange arthroplasty, ten patients (27.7% of 36 patients) unfortunately experienced recurrence or relapse of infection after an average of 31.3 months (range, 2.7-135.6 months). The rate of survivorship free from reinfection was 94.4% at six months, 84.8% at one year, and 73.6% at two years. Cox proportional hazard regression analysis demonstrated that the prosthesis-free interval (HR = 1.016, p = 0.037) and mean length of antifungal treatment (HR = 0.226, p = 0.046) were potential risk factors for failure.
Fungal PJIs led to devastating clinical outcomes despite even two-stage revision arthroplasty with the use of AICSs and antifungal medications.
展示在两次关节置换术联合抗真菌治疗后,患有真菌性假体周围关节感染(PJI)的患者的临床结果。
我们回顾性分析了 1999 年 1 月至 2017 年 10 月在一家中心接受初次全膝关节置换术(TKA)后发生真菌性 PJI 的 41 例患者的结果。在第一次切除关节成形术中,所有患者均植入了含抗真菌药物的骨水泥间隔物(AICS)。两次手术之间进行全身抗真菌治疗后,当患者临床稳定时,作为两阶段置换方案的一部分进行延迟再植入。我们将治疗成功定义为在没有任何 PJI 迹象的情况下功能良好的关节置换,并且在没有抗菌药物抑制的情况下至少随访两年。通过重复阴性培养以及炎症标志物恢复正常水平来确认成功治疗。
在最终随访时,治疗成功率为 63.4%。36 例(41 例患者中的 87.8%)在确认完全感染控制后符合第二期翻修标准。平均无假体间隔时间为 6.6 个月(范围 2.0-30.0 个月)。在两阶段置换关节成形术后随访期间,10 例(36 例患者中的 27.7%)不幸在平均 31.3 个月(范围 2.7-135.6 个月)后再次发生感染或复发。无再感染生存的概率在 6 个月时为 94.4%,1 年时为 84.8%,2 年时为 73.6%。Cox 比例风险回归分析表明,无假体间隔时间(HR=1.016,p=0.037)和平均抗真菌治疗时间(HR=0.226,p=0.046)是失败的潜在危险因素。
尽管使用 AICS 和抗真菌药物进行了两次关节置换术,但真菌性 PJI 仍导致了灾难性的临床结果。